Fluconazole for Vascular Response in Healthy Subjects

Overseen By Jeremy M Kellawan, PhD

Age: 18 - 65

Sex: Any

Trial Phase: Phase 4

Sponsor: University of Oklahoma

Must not be taking: Amiodarone, Sulphaphenazole, S-warfarin, others

Disqualifiers: Smoking, Hypertension, Cardiometabolic diseases, others

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 5 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 1

Duration: 1 day

30 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests how fluconazole (Diflucan) affects blood flow in healthy individuals during muscle activity. Researchers aim to determine if a specific body chemical, EDHF, influences blood flow during increased nerve activity in muscles. This understanding could aid future treatments for heart and metabolic diseases. Healthy individuals with normal blood pressure who do not smoke may qualify for this study. Participants will receive either fluconazole or a placebo to compare effects. As a Phase 4 trial, this research involves an FDA-approved medication and seeks to understand how fluconazole benefits more patients.

Will I have to stop taking my current medications?

Yes, you will need to stop taking certain medications, including Amiodarone, Sulphaphenazole, S-warfarin, Tolbutamine, Phenytoin, Lonafarnib, cardiometabolic medications, and sex hormone replacement medications, to participate in this trial.

What is the safety track record for fluconazole?

Research has shown that fluconazole is generally safe for people. Studies have found it to be well-tolerated in various treatments. Common side effects include diarrhea, stomach pain, and headache, which are usually mild. Serious side effects, such as skin reactions or liver damage, are rare but can occur.

The FDA has approved fluconazole for treating fungal infections, indicating its safety for intended uses. In this trial, participants receive a single dose of 150 mg, a common amount in medical treatments, which supports its known safety.

Overall, while fluconazole is widely used and considered safe, there is a risk of side effects, as with any medication. Participants will be monitored to ensure their safety during the study. ^{1 2 3 4 5}

Why are researchers enthusiastic about this study treatment?

Fluconazole is unique because it is being explored for its potential effects on vascular response, which is not its typical use. While fluconazole is traditionally an antifungal medication, researchers are curious about its ability to influence blood vessel function. Unlike standard treatments for vascular issues that may rely on different active ingredients or mechanisms, fluconazole's potential impact on blood vessels represents a novel application of an existing drug. This could lead to new insights into vascular health and expand the therapeutic uses of fluconazole beyond its current role in treating fungal infections.

What evidence suggests that fluconazole might be an effective treatment for vascular response?

Research has shown that fluconazole, a medication originally used to treat fungal infections, may affect blood vessels by influencing nerve signals that usually cause them to narrow. Scientists are exploring whether this effect could help with conditions related to nerve activity and blood flow. Animal studies, such as those with zebrafish, have shown that fluconazole can influence heart and blood vessel development, suggesting it might affect the cardiovascular system. However, limited information exists on its effects on human blood vessels concerning nerve activity. In this trial, some participants will receive a fluconazole tablet, while others will receive a placebo. The trial aims to determine if fluconazole can influence these processes, which could be important for treating heart-related conditions. ^{5 6 7 8 9}

Who Is on the Research Team?

Jeremy M Kellawan, PhD

Principal Investigator

University of Oklahoma

Are You a Good Fit for This Trial?

This trial is for healthy individuals with a BMI under 30, no cardiovascular or metabolic diseases, premenopausal women with regular cycles, and normal blood pressure. It excludes pregnant people, those on certain medications like Amiodarone or S-warfarin, hormone replacement therapy users, smokers/tobacco users within the last 6 months, and anyone on cardiometabolic meds.

Inclusion Criteria

Individuals with a BMI under 30 kg/m²

Individuals free of any form of autonomic dysfunction

Normotensive individuals (systolic blood pressure < 130 mmHg and/or diastolic blood pressure < 85 mmHg)

Exclusion Criteria

I am currently taking Amiodarone or Sulphaphenazole.

I am using sex hormone replacement therapy.

Smokers, tobacco users (regular use in the last 6 months)

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either a placebo or fluconazole to assess the impact of EDHF inhibition on vascular responses during LBNP and exercise

1 day

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Fluconazole

Trial Overview The study tests if Fluconazole (150 mg) affects how blood vessels respond to increased nerve activity that causes them to narrow. This response will be observed at rest and during exercise using a technique called lower body negative pressure in healthy participants.

How Is the Trial Designed?

Group I: fluconazole Experimental Treatment 1 Intervention

fluconazole tablet/pill 150 mg, single acute dose

Group II: Placebo Placebo Group 1 Intervention

250 mg pill microcrystalline Cellulose, single acute dose

Fluconazole is already approved in European Union, United States, Canada, Japan, China for the following indications:

Approved in European Union as Diflucan for:

• Candidiasis
• Cryptococcosis
• Histoplasmosis
• Coccidioidomycosis

Approved in United States as Diflucan for:

• Vaginal candidiasis
• Oropharyngeal candidiasis
• Esophageal candidiasis
• Cryptococcal meningitis

Approved in Canada as Diflucan for:

• Vaginal candidiasis
• Oropharyngeal candidiasis
• Esophageal candidiasis
• Cryptococcal meningitis

Approved in Japan as Diflucan for:

• Candidiasis
• Cryptococcosis
• Histoplasmosis
• Coccidioidomycosis

Approved in China as Diflucan for:

• Vaginal candidiasis
• Oropharyngeal candidiasis
• Esophageal candidiasis
• Cryptococcal meningitis

Who Is Running the Clinical Trial?

University of Oklahoma

Lead Sponsor

Trials

484

Recruited

95,900+

Published Research Related to This Trial

In a randomized double-blind, placebo-controlled trial involving 52 obese male smokers, 3 months of treatment with calcium dobesilate showed no significant effects on endothelial function, blood pressure, or markers of oxidation compared to placebo.

The study measured various vascular responses, including vasodilation and capillary recruitment, and found no meaningful differences, indicating that calcium dobesilate does not improve vascular function in this population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The effect of calcium dobesilate on vascular endothelial function, blood pressure, and markers of oxidation in obese male smokers: a placebo-controlled randomised clinical trial. Schram, MT., Stam, F., de Jongh, RT., et al.[2019]

The study demonstrated that both nitric oxide (NO) and calcium-activated potassium (K(Ca)) channels play a crucial role in regulating the diameter of human peripheral conduit arteries, as shown by significant changes in radial artery diameter when these pathways were inhibited.

The combined inhibition of NO synthesis and cytochrome P-450 (CYP) led to a greater reduction in artery diameter than either inhibitor alone, indicating an interaction between NO and a CYP-related endothelium-derived hyperpolarizing factor (EDHF) that helps maintain artery diameter in vivo.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Evidence for a basal release of a cytochrome-related endothelium-derived hyperpolarizing factor in the radial artery in humans. Bellien, J., Joannides, R., Iacob, M., et al.[2020]

The study identified that bradykinin induces vasodilation in human and porcine intramyocardial coronary micro-arteries through hyperpolarization of smooth muscle cells, rather than relying on nitric oxide, highlighting a unique mechanism of blood flow regulation.

The presence of longitudinally-arranged smooth muscle cells (l-SMCs) in the coronary artery wall facilitates rapid intercellular signaling, enhancing the coordination of blood flow in the coronary microvasculature.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Signaling and structures underpinning conducted vasodilation in human and porcine intramyocardial coronary arteries. Dora, KA., Lin, J., Borysova, L., et al.[2023]

In a study involving healthy volunteers, it was found that increased blood flow from hand skin heating led to decreased arterial stiffness, indicating that the endothelium plays a crucial role in regulating arterial tone during changes in blood flow.

The regulation of arterial stiffness was shown to involve both nitric oxide (NO) and cytochrome-derived epoxyeicosatrienoic acids, with specific inhibitors demonstrating that these factors work together to modulate arterial compliance and stiffness.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Arterial stiffness is regulated by nitric oxide and endothelium-derived hyperpolarizing factor during changes in blood flow in humans. Bellien, J., Favre, J., Iacob, M., et al.[2022]

In resistance arteries from cardiovascular disease patients, the effectiveness of the vasodilator bradykinin (BK) is influenced by the type of contractile stimulus, with enhanced relaxation observed in the presence of endothelin-1 (ET-1).

The study found that in ET-1-contracted arteries, the relaxing effect of BK shifts from relying on nitric oxide (NO) to hydrogen peroxide (H2O2), suggesting a potential mechanism for endothelial dysfunction in conditions with elevated ET-1 levels.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Endothelin-1 shifts the mediator of bradykinin-induced relaxation from NO to H2 O2 in resistance arteries from patients with cardiovascular disease. Leurgans, TM., Bloksgaard, M., Brewer, JR., et al.[2021]

Trelagliptin, a DPP-4 inhibitor, induces vasodilation in rabbit aortic rings in a dose-dependent manner, primarily through the activation of Kv7.X potassium channels and the SERCA pump.

The study suggests caution when prescribing trelagliptin to patients with hypotension and diabetes, as its vasodilatory effects could exacerbate low blood pressure.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The anti-diabetic drug trelagliptin induces vasodilation via activation of Kv channels and SERCA pumps. Heo, R., Seo, MS., An, JR., et al.[2021]

In a study involving 14 untreated essential hypertensive patients and 14 normotensive controls, it was found that epoxyeicosatrienoic acids (EETs) do not help regulate artery diameter in hypertensive patients as they do in healthy individuals, indicating a potential dysfunction in this compensatory mechanism.

While the inhibition of NO synthase reduced artery diameter in both groups, the combination of inhibiting both EETs and NO synthase did not further decrease artery diameter in hypertensive patients, suggesting that EETs are ineffective in compensating for altered NO availability in these individuals.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Impaired role of epoxyeicosatrienoic acids in the regulation of basal conduit artery diameter during essential hypertension. Bellien, J., Remy-Jouet, I., Iacob, M., et al.[2022]

Endothelium-derived hyperpolarizing factors, which activate K(+)(Ca) channels, play a significant role in maintaining resting blood flow and vasodilation, especially in individuals with multiple cardiovascular risk factors, as shown in a study involving 174 subjects.

In conditions where nitric oxide availability is reduced, such as hypercholesterolemia, these hyperpolarizing factors help compensate for the loss of vasodilatory function, indicating their importance in vascular health.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Endothelium-derived hyperpolarizing factor determines resting and stimulated forearm vasodilator tone in health and in disease. Ozkor, MA., Murrow, JR., Rahman, AM., et al.[2021]

Increased shear stress in the coronary microcirculation promotes the production of nitric oxide (NO), which helps limit vasoconstriction, particularly in small arteries, as shown in a study measuring microvascular diameter and flow velocity during vasoconstriction with endothelin or vasopressin.

The study found that inhibiting NO production with L-NMMA enhanced vasoconstriction, indicating that NO plays a crucial role in moderating constriction in response to shear stress, with small arteries being more responsive to this regulation than larger arterioles.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Nitric oxide limits coronary vasoconstriction by a shear stress-dependent mechanism. Stepp, DW., Merkus, D., Nishikawa, Y., et al.[2020]

The PM-1 automated perfusion myograph is a new in vitro model that allows researchers to test how drugs affect vascular function, including their impact on blood vessel relaxation and permeability.

In experiments, the myograph demonstrated that Ivermectin enhanced blood vessel relaxation, while L-NAME inhibited it, showcasing the model's ability to predict drug effects on vascular responses and potentially identify adverse reactions early in drug development.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A novel system for the investigation of microvascular dysfunction including vascular permeability and flow-mediated dilatation in pressurised human arteries. Moss, E., Lynagh, S., Smith, D., et al.[2013]

Citations

1. withpower.com withpower.com/trial/phase-4-1-2022-a0d50

Fluconazole for Vascular Response in Healthy Subjects Trial Overview The study tests if Fluconazole (150 mg) affects how blood vessels respond to increased nerve activity that causes them to narrow. This response ...

2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC7614594/

Impact of tolerance to fluconazole on treatment response in ... Among 44 patients included in the study, all-cause mortality was 29.5% at 30 days and 43.1% at 12 weeks. Forty-one isolates (93%) were ...

3. sciencedirect.com sciencedirect.com/science/article/pii/S0009279725000213

Fluconazole induces cardiovascular toxicity in zebrafish by ... The results demonstrated that fluconazole significantly inhibited the development of the heart and vasculature in zebrafish, and this ...

4. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC2533442/

Association of Fluconazole Pharmacodynamics with Mortality ... Multivariable analysis demonstrated an association between fluconazole resistance and mortality, but it did not reach statistical significance (odds ratio, 5.3; ...

5. sciencedirect.com sciencedirect.com/science/article/pii/S1198743X2400154X

The impact of the fluconazole trailing effect on ... The current study revealed that heavy trailing in C. albicans isolates is associated with persistent candidemia in patients receiving FLC treatment.

6. accessdata.fda.gov accessdata.fda.gov/drugsatfda_docs/label/2024/019949s072lbl.pdf

DIFLUCAN® (Fluconazole Tablets) (Fluconazole for Oral ... (See PRECAUTIONS.) Mean is based on data from 12 subjects as one of 13 subjects experienced a 2-fold increase in his prothrombin time response. Phenytoin ...

7. webmd.com webmd.com/drugs/2/drug-3780-5052/fluconazole-oral/fluconazole-oral/details

Fluconazole (Diflucan) - Uses, Side Effects, and More Common side effects include diarrhea, stomach pain, and headache. Serious side effects are rare, but can include skin reactions and liver damage ...

8. medsafe.govt.nz medsafe.govt.nz/profs/datasheet/d/DiflucancapIVsusp.pdf

Diflucan Data Sheet 4.8 Undesirable effects. Adults. Summary of safety profile. Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported in association with ...

9. go.drugbank.com go.drugbank.com/drugs/DB00196

Fluconazole: Uses, Interactions, Mechanism of Action Fluconazole 50 mg administered daily for up to 28 days in individuals of reproductive age has been show to have no effect on testosterone plasma concentrations ...